




Atp1a3-E818K-EM1 or Atp1a3-E818K-EM2 Genotyping Strategy

Animals have been engineered using the CRISPR/Cas9 technology. Most of the knockout alleles generated through this method will be obtained by deletion of a critical exon or by introduction of an indel (insertion/deletion) within the coding sequence of a critical exon (see picture below).




qPCR genotyping strategy

Standard PCR is the amplification of DNA between a pair of primers. Quantitative PCR employs the same principal as standard PCR, although it actually monitors the progress of the DNA synthesis as it occurs. The progress of the reaction is measured by using a Taqman probe. This is a short DNA oligo that is complimentary to part of the DNA sequence between the forward and reverse primers. At the 5' end of the probe there is a fluorescent reporter (R) and at the 3' end a quencher (Q). Whilst they are in close contact with each other there is no fluorescent signal.



As the forward primer is extended the reporter is cleaved from the probe resulting in a fluorescent signal being detected. Once the primer extends enough to release the quencher this signal is blocked. By using probes with different fluorescent signals multiple PCR assays can be multiplexed and run together.



Allele specific primer and probe amplification assay (ASPPAA) PCR

This is a new real-time PCR method (Billard *et al.*, 2012) in which an allele specific primer and an allele specific probe designed specific to the SNPs. The primer is designed such a way that its 3' end ends with a specific SNP. The probe is also designed specific to the SNPs at its 3' end giving a primer probe overlap. A maximum of 3nt overlap between a primer and probe is allowed.





Figure1: Figure showing principle of ASPPAA PCR. The dotted line indicates the position of the SNP.

PCR reaction plot



The number of cycles the PCR takes to reach a set threshold is known as the CT value. This is inversely correlated to the amount of template DNA in the sample.

e.g.
CT 25 = 2 x template DNA
CT 26 = 1 x template DNA
CT above 30 = no template represented in the sample

CT value can be used to determine how many copies of a particular allele samples have.

All our qPCR are run in duplicate. A FAM labelled genotyping assay is run in multiplex with a VIC labelled internal control Dot1l.

References:

- Billard A., Laval V., Fillinger S., Leroux P., Lachaise H., Beffa R., et al. (2012). The allele-specific probe and primer amplification assay, a new real-time PCR method for fine quantification of single-nucleotide polymorphisms in pooled DNA. *Appl. Environ. Microbiol.* 78 1063–1068. 10.1128/AEM.06957-11

Atp1a3-E818K-EM1 or Atp1a3-E818K-EM2 Genotyping Strategy

Samples are genotyped with both WT and Mutant assays. These are FAM labelled assays that are designed to detect the critical exon that has been modified. If the animal contains the modified allele the copy number of the WT assay should drop by 1 and the mutant assay should raise by 1. For autosomal genes that have been targeted this means the following

WT= 2 copies of the WT assay and 0 copies of the Mutant assay

HET = 1 copy of the WT assay and 1 copy of the Mutant assay

HOM = 0 copies of the WT assay and 2 copies of the Mutant assay

Atp1a3-E818K-EM1 or Atp1a3-E818K-EM2 CRISPR/Cas9 mutant in which SNPs are as highlighted

WT	CTGCAATCTCCCTGGCCTACGAGGCTGCC	CG	AGAGCGACATCATGAAGAGGCAGCCCAG
Mutant	CTGCAATCTCCCTGGCCTACGAGGCTGC	AA	AGAGCGACATCATGAAGAGGCAGCCCAG

Atp1a3-E818K-WT1 assay (FAM labelled probe)

CCATCCAGGTCCCTGCAATCTCCCTGGC **CTACGAGGCTGCC** **GAGA** GCGACATCATGAAGAGGCAGCCCAGGAACC
CACGCACAGACAAACTGGTCAACGAAAGGCTCATCAGCATGGCCTACGGGCAGATTGGTGAGGACTGCCGGGGCT

Primer 1 = CATCCAGGTCCCTGCAATCTC

Primer 2 = GCCTCTTCATGATGTCGCTCTC

Probe = CTACGAGGCTGC **CGAGA**

Allele specific primer and probes

Atp1a3-E818K-MUT1 assay (FAM labelled probe)

CCATCCAGGTCCCTGCAATCTCCCT **GGCCTACGAGGCTGC** **AA** AGAGCGACATCATGAAGAGGCAGGCCAGGAACC
CACGCACAGACAAACTGGTCAACGAAAGGCTCATCAGCATGGCCTACGGGCAGATTGGTGAGGACTGCCGGGGCT

Primer 1 = GGCCTACGAGGCTGC **AA**

Primer 2 = GAGCCTTCGTTGACCAGTTG

Probe = AGAGCGACATCATGAAGAGGCAGCC

All qPCR assays are run in duplex with a VIC labelled internal control, Dot1l

Dot1l internal control (VIC labelled)

CCCCCTAGTCGTTCTGTTAG **TAGTTGGC** ATCCTTATGCTTCATCTTACAGT **CGACTTGAGAGCTGG** CCCTGA
ATGGTCGTGCTGGGGC AAGGCTTATTTCAGGCGTAGCACACATGGTGGCCAATGGGACTCTGTAGGATCTGCC


Primer 1 = GCCCCAGCACGACCATT

Primer 2 = TAGTTGGCATTCTTATGCTTCATC

Probe = CCAGCTCTCAAGTCG

qPCR master mix

ABI GTX Taqman master mix	5µl
Primers Dot1L_2F (20µM)	0.225µl
Primers Dot1L_R (20µM)	0.225µl
Probe DotL_2M (5µM)	0.2µl
FAM Assay (probe 5µM & primers 15µM each)	0.3µl
ddH2O	1.55µl
DNA (1/10 dilution of ABI Sample-to-SNP prep)	2.5µl

Atp1a3-E818K-EM1 or Atp1a3-E818K-EM2 copy called result, image showing both replicates and controls (240061)

Version No.

1

Date:

22/02/19

Created/Updated by:

Daniel Ford

Approved by:

Debbie Williams

Name of Mouse model or mutation:**ATP1A3-E818K-EM1-B6N****ATP1A3-E818K-EM2-C3H****Description:**

Point mutation generated using CRISPR/Cas9 reagents.

Type of mutation:

Point mutation: E818K

Sequence details**Atp1a3 WT:**


GGCTCCATTAGACCCAAGTTCTAACGCCTGCTCCTCTGCTCCTCCACTACAGGCCGCTGATCTT
GACAACCTGAAGAAATCCATCGCCTACACTCTGACTAGCAACATCCCTGAGATCACACCCCTCTGCT
CTTCATCATGGCTAACATCCCCTGCCTCTGGCACCACCATCACCCTCTGCATTGACCTGGTACCG
ACATGGTAAGCCTGGCTGCTACTAAAGGCTGGAGAGGGCCACCCCCACACGCTTGCGCCCTCTCT
TCTCTCCACTCACACAGCCTGCCTCTCTCCATCCAGGTCCCTGCAATCTCCCTGGCCTACGAGGCTGC
CGAGAGCGACATCATGAAGAGGGCAGCCCAGGAACCCACGCACAGACAAACTGGTCAACGAAAGGC
TCATCAGCATGGCCTACGGGAGATTGGTGAGGACTGCCGGGCTCAGAACCAAGGACCAGTCCAG
CAGAGTGGACGTGTACCTGGCCTGAGGGCTTAAAGCACGGGACAAGAGACCTATGTCCCTTCCT
ACTTTGGGAGTGGGGACATAGGCAGAGCCATAAAGAGCAAAGCTCATGAAGCCGAAGCAACCA
AAGTCGAGACTCCTCTGGAGCCTCGTTGTTAAGTGTCTAAACAAACCAATCACTGGCTTCCGA
TTCACTATGTAAGCAGAATAGCCTGAACCTCTGATCCTCTGCCTCCATTCCAAGTGTGGATT
ACAGGCCTGTGCTGCAATACTAAATTGATTACTAACTGTGGATTAAACCCGGGTTTATTCCATTCT
AGGCAAGCCCTCTGCCATGGTACATTCCAAATCTTACCTTTGTTGAGATGGGGCGGGGGT
GTCTCACTAAATTGG

ATP1A3-E818K-EM1-B6N or ATP1A3-E818K-EM2-C3H:

GGCTCCATTAGACCCAAGTTCTAACGCCTGCTCCTCTGCTCCTCCACTACAGGCCGCTGATCTT
GACAACCTGAAGAAATCCATCGCCTACACTCTGACTAGCAACATCCCTGAGATCACACCCCTCTGCT
CTTCATCATGGCTAACATCCCCTGCCTCTGGCACCACCATCACCCTCTGCATTGACCTGGTACCG
ACATGGTAAGCCTGGCTGCTACTAAAGGCTGGAGAGGGCCACCCCCACACGCTTGCGCCCTCTCT
TCTCTCCACTCACACAGCCTGCCTCTCTCCATCCAGGTCCCTGCAATCTCCCTGGCCTACGAGGCTGC
AAAGAGCGACATCATGAAGAGGGCAGCCCAGGAACCCACGCACAGACAAACTGGTCAACGAAAGGC
TCATCAGCATGGCCTACGGGAGATTGGTGAGGACTGCCGGGCTCAGAACCAAGGACCAGTCCAG
CAGAGTGGACGTGTACCTGGCCTGAGGGCTTAAAGCACGGGACAAGAGACCTATGTCCCTTCCT
ACTTTGGGAGTGGGGACATAGGCAGAGCCATAAAGAGCAAAGCTCATGAAGCCGAAGCAACCA
AAGTCGAGACTCCTCTGGAGCCTCGTTGTTAAGTGTCTAAACAAACCAATCACTGGCTTCCGA

TTCACTATGTAAGCAGAATGCCCTGAACCTCTGATCCTGCCTCCATTCCAAGTGCTGGATT
ACAGGCCTGTGCTGCAATACTAAATTGATTACTAACTGTGGATTAAACCCGGGGTTCATCCATTCT
AGGCAAGCCCTGCCATGGTACATTCCAAATCTTACCTTGTGAGATGGGGCGGGGGT
GTCTCACTAAATTGG

ATP1A3-E818K-EM1-B6N Heterozygous F1 animal sequence trace:



Nucleotide Alignment:

Atp1a3_WT	: GGCTCCATTAGACCCAAGTTCTAACGCCGCTCCTCTGCTCCACTACAGGCCGCTGATTTGACAACCTGAAGAAATCCATGCCCTACACTCTGACTAGCAACATCCCAGATCACACCCCT
Atp1a3_E818K	: GGCTCCATTAGACCCAAGTTCTAACGCCGCTCCTCTGCTCCACTACAGGCCGCTGATTTGACAACCTGAAGAAATCCATGCCCTACACTCTGACTAGCAACATCCCAGATCACACCCCT GGCTCCATTAGACCCAAGTTCTAACGCCGCTCCTCTGCTCCACTACAGGCCGCTGATTTGACAACCTGAAGAAATCCATGCCCTACACTCTGACTAGCAACATCCCAGATCACACCCCT
* 20 * 40 * 60 * 80 * 100 * 120	
Atp1a3_WT	: CCTGCTCTTCATCATGGCTAACATCCCAGTGCCTCTGGCACCATCACCATCCTGCATTGACCTGGGTACCGACATGGTAAGCCTGGCTGCTACTAAAGGCTGGAGAGGGCACCCCCACACGCTTGC
Atp1a3_E818K	: CCTGCTCTTCATCATGGCTAACATCCCAGTGCCTCTGGCACCATCACCATCCTGCATTGACCTGGGTACCGACATGGTAAGCCTGGCTGCTACTAAAGGCTGGAGAGGGCACCCCCACACGCTTGC CCTGCTCTTCATCATGGCTAACATCCCAGTGCCTCTGGCACCATCACCATCCTGCATTGACCTGGGTACCGACATGGTAAGCCTGGCTGCTACTAAAGGCTGGAGAGGGCACCCCCACACGCTTGC
* 140 * 160 * 180 * 200 * 220 * 240 * 260	
Atp1a3_WT	: GCCCCTCTCTTCTCCACTCACACAGCCTGCCTCTCCCCTCAGGTCCCTGCAATCTCCCTGGCTACGAGGCTGCAGAGCGACATCATGAAGAGGCAGCCAGGAACCCACGACAGACAAAC
Atp1a3_E818K	: GCCCCTCTCTTCTCCACTCACACAGCCTGCCTCTCCCCTCAGGTCCCTGCAATCTCCCTGGCTACGAGGCTGCAGAGCGACATCATGAAGAGGCAGCCAGGAACCCACGACAGACAAAC GCCCCTCTCTTCTCCACTCACACAGCCTGCCTCTCCCCTCAGGTCCCTGCAATCTCCCTGGCTACGAGGCTGCAGAGCGACATCATGAAGAGGCAGCCAGGAACCCACGACAGACAAAC
* 280 * 300 * 320 * 340 * 360 * 380 *	
Atp1a3_WT	: TGGTCAACGAAAGGCTCATCAGCATGGCTACGGGAGATTGGTGAGGACTGCCGGGGCTCAGAACCAAGGACCAGTCCAGCAGAGTGGACGTGACCTGGCTGAGGGCTAAAGCACGGGACAAGAGA
Atp1a3_E818K	: TGGTCAACGAAAGGCTCATCAGCATGGCTACGGGAGATTGGTGAGGACTGCCGGGGCTCAGAACCAAGGACCAGTCCAGCAGAGTGGACGTGACCTGGCTGAGGGCTAAAGCACGGGACAAGAGA TGGTCAACGAAAGGCTCATCAGCATGGCTACGGGAGATTGGTGAGGACTGCCGGGGCTCAGAACCAAGGACCAGTCCAGCAGAGTGGACGTGACCTGGCTGAGGGCTAAAGCACGGGACAAGAGA
* 400 * 420 * 440 * 460 * 480 * 500 * 520	
Atp1a3_WT	: CCTATGTCCTTCCCTACTTTGGGAGTGGGGACATAGGCAGAGCCATAAGAGCAAAGCTCATGAAGCCGAAGCAACCAAAGTCGAGACTCCTCTGGAGCCTCGTTGTTAAGTGTCTCAA
Atp1a3_E818K	: CCTATGTCCTTCCCTACTTTGGGAGTGGGGACATAGGCAGAGCCATAAGAGCAAAGCTCATGAAGCCGAAGCAACCAAAGTCGAGACTCCTCTGGAGCCTCGTTGTTAAGTGTCTCAA CCTATGTCCTTCCCTACTTTGGGAGTGGGGACATAGGCAGAGCCATAAGAGCAAAGCTCATGAAGCCGAAGCAACCAAAGTCGAGACTCCTCTGGAGCCTCGTTGTTAAGTGTCTCAA
* 540 * 560 * 580 * 600 * 620 * 640 *	
Atp1a3_WT	: CAACCAATCAGGCCGCTCCGATTCACTATGTAAGCAGAATAGCCGTAACCTCTGATCCTCTGCCATTCCAAAGTGTGGATTACAGGCCGTGCTGCAATACTAAATTGATTACTAAGTGTGG
Atp1a3_E818K	: CAACCAATCAGGCCGCTCCGATTCACTATGTAAGCAGAATAGCCGTAACCTCTGATCCTCTGCCATTCCAAAGTGTGGATTACAGGCCGTGCTGCAATACTAAATTGATTACTAAGTGTGG CAACCAATCAGGCCGCTCCGATTCACTATGTAAGCAGAATAGCCGTAACCTCTGATCCTCTGCCATTCCAAAGTGTGGATTACAGGCCGTGCTGCAATACTAAATTGATTACTAAGTGTGG
* 660 * 680 * 700 * 720 * 740 * 760 * 780	
Atp1a3_WT	: ATTAACCCGGGGTTTCATCCATTCTAGGAAGCCCTCTGCCATGGTACATTCCAAATCTTACCTTTGTTGAGATGGGGGGGGGGGTGTCCTCACTAAATTGG
Atp1a3_E818K	: ATTAACCCGGGGTTTCATCCATTCTAGGAAGCCCTCTGCCATGGTACATTCCAAATCTTACCTTTGTTGAGATGGGGGGGGGGGTGTCCTCACTAAATTGG ATTAACCCGGGGTTTCATCCATTCTAGGAAGCCCTCTGCCATGGTACATTCCAAATCTTACCTTTGTTGAGATGGGGGGGGGGGTGTCCTCACTAAATTGG
* 800 * 820 * 840 * 860 * 880	

Predicted Protein Alignment:

* 20 * 40
Atpla3_WT : VPAISLAYEAA SDIMKRQPRNPRTDKLVLNERLISMAYGQI
Atpla3_E818K : VPAISLAYEAA SDIMKRQPRNPRTDKLVLNERLISMAYGQI
VPAISLAYEAA SDIMKRQPRNPRTDKLVLNERLISMAYGQI

QC strategy employed at Harwell to check the edited allele:

Genomic DNA was extracted from ear clip biopsies and amplified in a PCR reaction using the following conditions/primer sequences:

Geno_Atp1a3_F3 (5'-3')	GGCTCCATTAGACCCCCAAGTT
Geno_Atp1a3_R3 (5'-3')	CCAATTAGTGAGACACCCCCG
Taq Polymerase used	Roche Expand Long Range DNTPack
Annealing Temperature (°C)	64
Elongation time (min)	1
WT product size (bp)	889
Mutant product size (bp)	889
Notes	

All amplicons were sent for Sanger sequencing to check for integration of the donor oligo sequence at the target site. F1 sequences should be heterozygous unless on sex chromosome.

Copy counting of the donor sequence was carried out by ddPCR at the F1 stage to confirm donor oligos were inserted once on target into the genome. The following Taqman assay was used to copy count the donor sequence compared against a VIC-labelled reference assay for Dot1l:

Assay name	Atp1a3-E818K-UNIV1
Forward Primer (5'-3')	CCATCCAGGTCCCTGCAA
Reverse Primer (5'-3')	GTTGACCAGTTGTCTGTGCGT
Probe (5'-3')	TCTCCCTGGCCTACGAGGCT
Label	FAM-BHQ1

The ddPCR assay recognises sequence common to both the WT Atp1a3 and the E818K mutant. Therefore, WT controls and correctly targeted F1 E818K heterozygote animals will call at 2 copies.

Assay name	Atp1a3-E818K-MUT1
Forward Primer (5'-3')	GGCCTACGAGGCTGCAA
Reverse Primer (5'-3')	GAGCCTTCGTTGACCAGTTG
Probe (5'-3')	AGAGCGACATCATGAAGAGGCAGCC
Label	FAM-BHQ1

The ddPCR assay is specific to the Atp1a3 E818K mutation. Therefore, WT controls will call at 0 copies and correctly targeted F1 E818K heterozygote animals will call at 1 copy.

Reference Assay Name	Dot1l
Forward primer (5'-3')	GCCCCAGCACGACCATT
Reverse primer (5'-3')	TAGTTGGCATCCTTATGCTTCATC
Probe (5'-3')	CCCAACAGGCCTGGATTCTCAATGC
Label	VIC

VIC-labelled reference assay for Dot1l gene.